A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with merkel cell cancer that has spread to other places in the body.
The purpose of this study is to describe the progression-free survival (PFS) of stereotactic body radiation therapy (SBRT) + pembrolizumab (MK-3475) compared to MK-3475 alone in advanced/metastatic merkel cell carcinoma (MCC) patients.
Participants will not be paid for their participation.
- IRB Number: 1808895146 (A091605)
- Research Study Identifier: TX9083
- Principal Investigator: Ahmad Al-Hader, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required